ESR1 and triple-negative breast carcinoma: We confirmed the expression of EphA5 in lung, ovarian, and pancreatic cancers and found EphA5 is also expressed in several other human solid tumors, including 84% of breast (estrogen-receptor-positive, n = 23 of 26 [88%]; triple-negative breast cancer [TNBC], n = 18 of 23 [78%]), 70% of gastric (n = 7 of 10), and 68% of colon (n = 15 of 22) cancers, among others (Figure 1).